Topical capsaicin (high concentration) for chronic neuropathic pain in adults

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 1, 2017, Pages

  Derry, Sheena ^a   Rice, Andrew S C ^b,c   Cole, Peter ^d   Tan, Toni ^e   Moore, R Andrew ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^d CHURCHILL HOSPITAL   (United Kingdom)

^e NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSAICIN; ANALGESIC AGENT; OINTMENT;

ADULT; ANALGESIA; CONCENTRATION RESPONSE; DIABETIC NEUROPATHY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; NEUROPATHIC PAIN; NEUROPATHY; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN BURNING SENSATION; SKIN PAIN; SKIN REDNESS; SYSTEMATIC REVIEW; TRANSDERMAL PATCH; TREATMENT DURATION; CHRONIC PAIN; COMPLICATION; DIABETIC NEUROPATHIES; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; META ANALYSIS; NEURALGIA; NEURALGIA, POSTHERPETIC; NUMBERS NEEDED TO TREAT; OINTMENT; PAIN, POSTOPERATIVE; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADULT; ANALGESICS; CAPSAICIN; CHRONIC PAIN; DIABETIC NEUROPATHIES; HIV INFECTIONS; HUMANS; NEURALGIA; NEURALGIA, POSTHERPETIC; NUMBERS NEEDED TO TREAT; OINTMENTS; PAIN, POSTOPERATIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85009376440     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD007393.pub4     Document Type: Review

References (97)

1. Backonja M, Wallace MS, Blonsky ER, Cutler BJ, Malan P Jr, Rauck R, et al. NGX-4010 C107 Study Group. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurology 2008;7(12):1106-12. [2968931; DOI: 10.1016/S1474-4422(08)70228-X]
2. Bischoff JM, Ringsted TK, Petersen M, Sommer C, Uçeyler N, Werner MU. A capsaicin (8%) patch in the treatment of severe persistent inguinal postherniorrhaphy pain: a randomized, double-blind, placebo-controlled trial. PLoS One 2014;9(10):e109144. [2968933; DOI: 10.1371/journal.pone.0109144]
3. Brown S, Simpson DM, Moyle G, Brew BJ, Schifitto G, Larbalestier N, et al. NGX-4010, a capsaicin 8% patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: integrated analysis of two phase III, randomized, controlled trials. AIDS Research and Therapy 2013;10(1):5. [4498393; DOI: 10.1186/1742-6405-10-5]
4. Clifford DB, Simpson DM, Brown S, Moyle G, Brew BJ, Conway B, et al. NGX-4010 C119 Study Group. A randomized, double-blind, controlled study of NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy. Journal of Acquired Immune Deficiency Syndromes 2012;589(2):126-33. [2968935; DOI: 10.1097/QAI.0b013e31823e31f7]
5. Irving GA, Backonja MM, Dunteman E, Blonsky ER, Vanhove GF, Lu SP, et al. NGX-4010 C117 Study Group. A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. Pain Medicine 2011;12(1):99-109. [2968937; DOI: 10.1111/j.1526-4637.2010.01004.x]
6. Brown S, Simpson DM, Moyle G, Brew BJ, Schifitto G, Larbalestier N, et al. NGX-4010, a capsaicin 8% patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: integrated analysis of two phase III, randomized, controlled trials. AIDS Research and Therapy 2013;10(1):5. [4498394; DOI: 10.1186/1742-6405-10-5]
7. Simpson DM, Brown S, Tobias J, NGX-4010 C107 Study Group. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology 2008;70(24):2305-13. [2968939; DOI: 10.1212/01.wnl.0000314647.35825.9]
8. Astellas Pharma Inc (Responsible party). A phase III, double-blind, randomized, placebo-controlled, multicenter study evaluating the efficacy and safety of QUTENZA® in subjects with painful diabetic peripheral neuropathy. clinicaltrials.gov/ct2/show/NCT01533428 Date first received: 12 February 2012. [Astellas ID: E05-CL-3004; 2968941; CTG: NCT01533428]
9. Astellas PharmaEurope BV (Sponsor). A phase III, double-blind, randomized, placebo-controlled, multicenter study evaluating the efficacy and safety of QUTENZA® in subjects with painful diabetic peripheral neuropathy (clinical study results). www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=76 Date first received: 6 February 2012. [Astellas ID: E05-CL-3004; 2968942]
10. Simpson DM, Robinson-Papp J, Van J, Stoker M, Jacobs H, Snijder RJ, et al. Capsaicin 8% patch in painful diabetic peripheral neuropathy: a randomized, double-blind, placebo-controlled study. Journal of Pain 2016 Oct 13 [Epub ahead of print]. [4498395; DOI: 10.1016/j.jpain.2016.09.008]
11. Webster LR, Tark M, Rauck R, Tobias JK, Vanhove GF. Effect of duration of postherpetic neuralgia on efficacy analyses in a multicenter, randomized, controlled study of NGX-4010, an 8% capsaicin patch evaluated for the treatment of postherpetic neuralgia. BMC Neurology 2010;10:92. [2968944; DOI: 10.1186/1471-2377-10-92]
12. Webster LR, Malan TP, Tuchman MM, Mollen MD, Tobias JK, Vanhove GF. A multicenter, randomized, double-blind, controlled dose finding study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. Journal of Pain 2010;11(10):972-82. [2968946; DOI: 10.1016/j.jpain.2010.01.270]
13. Backonja MM, Malan TP, Vanhove GF, Tobias JK, C102/106 Study Group. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled study with an open-label extension. Pain Medicine 2010;11(4):600-8. [2968948; DOI: 10.1111/j.1526-4637.2009.00793.x]
14. Vanhove T. A multicenter randomized, double-blind, controlled study to evaluate safety, tolerability and preliminary efficacy of two capsaicin concentration variations of NGX-1998 (10% or 20% w/w) in subjects with postherpetic neuralgia (PHN). clinicaltrials.gov/ct2/show/NCT01228838 Date first received: 25 October 2010. [2968950; CTG: NCT01228838; NeurogesX ID: C204]
15. Webster L, Bhattacharya S, Wallace M, Wells B, Tobias J, Babbar S. Efficacy and safety of NGX-1998, a novel topical liquid formulation of capsaicin, in patients with postherpetic neuralgia: results of a multi-center, placebo-controlled trial. Journal of Pain 2012;13 (4 Suppl 1):S72. [2968951; DOI: 10.1016/j.jpain.2012.01.300]
16. Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. British Journal of Anaesthetics 2011;107(4):490-502. [DOI: 10.1093/bja/aer260]
17. Azevedo LF, Costa-Pereira A, Mendonça L, Dias CC, Castro-Lopes JM. The economic impact of chronic pain: a nationwide population-based cost-of-illness study in Portugal. European Journal of Health Economics 2016;17(1):87-98. [DOI: 10.1007/s10198-014-0659-4]
18. Baron R, Wasner G, Binder A. Chronic pain: genes, plasticity, and phenotypes. Lancet Neurology 2012;11(1):19-21. [DOI: 10.1016/S1474-4422(11)70281-2]
19. Bouhassira D, Lantéri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008;136(3):380-7. [DOI: 10.1016/j.pain.2007.08.013]
20. Bouhassira D, Chassany O, Gaillat J, Hanslik T, Launay O, Mann C, et al. Patient perspective on herpes zoster and its complications: an observational prospective study in patients aged over 50 years in general practice. Pain 2012;153(2):342-9. [DOI: 10.1016/j.pain.2011.10.026]
21. Burness CB, McCormack PL. Capsaicin 8% patch: a review in peripheral neuropathic pain. Drugs 2016;76:123-34. [DOI: 10.1007/s40265-015-0520-9]
22. Calvo M, Dawes JM, Bennett DL. The role of the immune system in the generation of neuropathic pain. Lancet Neurology 2012;11(7):629-42. [DOI: 10.1016/S1474-4422(12)70134-5]
23. Collins SL, Moore RA, McQuay HJ. The visual analogue pain intensity scale: what is moderate pain in millimetres?. Pain 1997;72(1-2):95-7.
24. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ (Clinical Research Ed) 1995;310:452-4.
25. Dechartres A, Trinquart L, Boutron I, Ravaud P. Influence of trial sample size on treatment effect estimates: meta-epidemiological study. BMJ 2013;346:f2304. [DOI: 10.1136/bmj.f2304]
26. Demant DT, Lund K, Vollert J, Maier C, Segerdahl M, Finnerup NB, et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study. Pain 2014;155(11):2263-73. [DOI: 10.1016/j.pain.2014.08.014]
27. Derry S, Moore RA. Topical capsaicin (low concentration) for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD010111]
28. Derry S, Wiffen PJ, Moore RA, Quinlan J. Topical lidocaine for neuropathic pain in adults. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD010958.pub2]
29. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain 2008;9(2):105-21. [DOI: 10.1016/j.jpain.2007.09.005]
30. Edwards JE, McQuay HJ, Moore RA, Collins SL. Reporting of adverse effects in clinical trials should be improved: lessons from acute postoperative pain. Journal of Pain and Symptom Management 1999;18(6):427-37. [DOI: 10.1016/S0885-3924(99)00093-7]
31. Astellas PharmaEurope BV (Sponsor). QUTENZATM versus pregabalin in subjects with peripheral neuropathic pain: an open-label, randomized, multicenter, non-inferiority efficacy and tolerability study. www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=83 Date first received: 11 July 2012. [EudraCT number: 2011-005872-41]
32. eMC Qutenza 179mg cutaneous patch. www.medicines.org.uk/emc/medicine/23156/SPC/qutenza 179mg cutaneous patch/ (accessed 28 April 2012).
33. Effective Practice, Organisation of Care (EPOC). 23. Worksheets for preparing a Summary of Findings using GRADE. Resources for review authors. Oslo: Norwegian Knowledge Centre for the Health Services. Available at: epoc.cochrane.org/epoc-specific-resources-review-authors (accessed 30 November 2016) 2015.
34. US Department of Health and Human Services. Guidance for industry: skin irritation and sensitization testing of generic transdermal drug products. www.fda.gov/ohrms/dockets/98fr/990236Gd.pdf (accessed 13 December 2016).
35. Finnerup NB, Scholz J, Attal N, Baron R, Haanpää M, Hansson P, et al. Neuropathic pain needs systematic classification. European Journal of Pain 2013;17(7):953-6. [DOI: 10.1002/j.1532-2149.2012.00282.x]
36. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurology 2015;14(2):162-73. [DOI: 10.1016/S1474-4422(14)70251-0]
37. Gustorff B, Dorner T, Likar R, Grisold W, Lawrence K, Schwarz F, et al. Prevalence of self-reported neuropathic pain and impact on quality of life: a prospective representative survey. Acta Anaesthesiological Scandinavica 2008;52(1):132-6.
38. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 7. Rating the quality of evidence - inconsistency. Journal of Clinical Epidemiology 2011;64(12):1294-302. [DOI: 10.1016/j.jclinepi.2011.03.017]
39. Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso-Coello P, et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. Journal of Clinical Epidemiology 2013;66(2):151-7. [DOI: 10.1016/j.jclinepi.2012.01.006]
40. Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, et al. GRADE guidelines: 12. Preparing summary of findings tables - binary outcomes. Journal of Clinical Epidemiology 2013;66(2):158-72. [DOI: 10.1016/j.jclinepi.2012.01.012]
41. Gülfe A, Kristensen LE, Saxne T, Jacobsson LT, Petersson IF, Geborek P. Utility-based outcomes made easy: the number needed per quality-adjusted life year gained. An observational cohort study of tumor necrosis factor blockade in inflammatory arthritis from Southern Sweden. Arthritis Care and Research 2010;62(10):1399-406. [DOI: 10.1002/acr.20235]
42. Hall GC, Carroll D, McQuay HJ. Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002-2005. BMC Family Practice 2008;9:26. [DOI: 10.1186/1471-2296-9-26]
43. Hall GC, Morant SV, Carroll D, Zahava LG, McQuay HJ. An observational descriptive study of the epidemiology and treatment of neuropathic pain in a UK general population. BMC Family Practice 2013;14:28. [DOI: 10.1186/1471-2296-14-28]
44. Helfert SM, Reimer M, Höper J, Baron R. Individualized pharmacological treatment of neuropathic pain. Clinical Pharmacology and Therapeutics 2015;97(2):135-42. [DOI: 10.1002/cpt.19]
45. Higgins JPT, Green S, editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
46. Hoffman DL, Sadosky A, Dukes EM, Alvir J. How do changes in pain severity levels correspond to changes in health status and function in patients with painful diabetic peripheral neuropathy?. Pain 2010;149(2):194-201. [DOI: 10.1016/j.pain.2009.09.017]
47. Ikenberg R, Hertel N, Moore RA, Obradovic M, Baxter G, Conway P, et al. Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine. Journal of Medical Economics 2012;15(4):724-36. [DOI: 10.3111/13696998.2012.670174]
48. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17:1-12. [DOI: 10.1016/0197-2456(95)00134-4]
49. Jensen TS, Baron R, Haanpää M, Kalso E, Loeser JD, Rice AS, et al. A new definition of neuropathic pain. Pain 2011; Vol. 152, issue 10:2204-5. [DOI: 10.1016/j.pain.2011.06.017]
50. Kalso E, Aldington DJ, Moore RA. Drugs for neuropathic pain. BMJ 2013;347:f7339. [DOI: 10.1136/bmj.f7339]
51. Katusic S, Williams DB, Beard CM, Bergstralh EJ, Kurland LT. Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia: similarities and differences, Rochester, Minnesota, 1945-1984. Neuroepidemiology 1991;10:276-81. [DOI: 10.1159/000110284]
52. Kern KU, Nowack W, Poole C. Treatment of neuropathic pain with the capsaicin 8% patch: is pretreatment with lidocaine necessary?. Pain Practice 2014;14(2):E42-50. [DOI: 10.1111/papr.12143]
53. Knolle E, Zadrazil M, Kovacs GG, Medwed S, Scharbert G, Schemper M. Comparison of cooling and EMLA to reduce the burning pain during capsaicin 8% patch application: a randomized, double-blind, placebo-controlled study. Pain 2013;154(12):2729-36. [DOI: 10.1016/j.pain.2013.08.001]
54. Koopman JS, Dieleman JP, Huygen FJ, de Mos M, Martin CG, Sturkenboom MC. Incidence of facial pain in the general population. Pain 2009;147(1-3):122-7. [DOI: 10.1016/j.pain.2009.08.023]
55. L'Abbé KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Annals of Internal Medicine 1987;107:224-33. [DOI: 10.7326/0003-4819-107-2-224]
56. Loke YK, Derry S. Reporting of adverse drug reactions in randomised controlled trials - a systematic survey. BMC Clinical Pharmacology 2001;1:3. [DOI: 10.1186/1472-6904-1-3]
57. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD007115.pub3]
58. Moore RA, Gavaghan D, Tramèr MR, Collins SL, McQuay HJ. Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain 1998;78(3):209-16. [DOI: 10.1016/S0304-3959(98)00140-7]
59. Moore RA, Derry S, Makinson GT, McQuay HJ. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Research and Therapy 2005;7(3):R644-65. [DOI: 10.1186/ar1704]
60. Moore RA, Barden J, Derry S, McQuay HJ. Managing potential publication bias. In: McQuay HJ, Kalso E, Moore RA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15-23. [ISBN: 978-0-931092-69-5]
61. Moore RA, Derry S, McQuay HJ. Discontinuation rates in clinical trials in musculoskeletal pain: meta-analysis from etoricoxib clinical trial reports. Arthritis Research and Therapy 2008;10(3):R53. [DOI: 10.1186/ar2422]
62. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007076.pub2]
63. Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2011, Issue 3. [DOI: 10.1002/14651858.CD007938.pub2]
64. Moore RA, Gaskell H, Rose P, Allan J. Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data. BMC Blood Disorders 2011;11:4. [DOI: 10.1186/1471-2326-11-4]
65. Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.CD008242.pub2]
66. Moore RA, Straube S, Eccleston C, Derry S, Aldington D, Wiffen P, et al. Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses. Pain 2012;153(2):265-8. [DOI: 10.1016/j.pain.2011.10.004]
67. Moore A, Derry S, Eccleston C, Kalso E. Expect analgesic failure; pursue analgesic success. BMJ 2013;346:f2690. [DOI: 10.1136/bmj.f2690]
68. Moore RA, Straube S, Aldington D. Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome. Anaesthesia 2013;68(4):400-12. [DOI: 10.1111/anae.12148]
69. Moore RA, Derry S, Taylor RS, Straube S, Phillips CJ. The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain. Pain Practice 2014;14(1):79-94. [DOI: 10.1111/papr.12050]
70. Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2014, Issue 4. [DOI: 10.1002/14651858.CD007938.pub3]
71. Moore RA, Cai N, Skljarevski V, Tölle TR. Duloxetine use in chronic painful conditions - individual patient data responder analysis. European Journal of Pain 2014;18(1):67-75. [DOI: 10.1002/j.1532-2149.2013.00341.x]
72. Morris JA, Gardner MJ. Calculating confidence intervals for relative risk, odds ratios and standardised ratios and rates. In: Gardner MJ, Altman DG editor(s). Statistics with Confidence - Confidence Intervals and Statistical Guidelines. London: British Medical Journal, 1995:50-63.
73. Mou J, Paillard F, Turnbull B, Trudeau J, Stoker M, Katz NP. Efficacy of Qutenza® (capsaicin) 8% patch for neuropathic pain: a meta-analysis of the Qutenza Clinical Trials Database. Pain 2013;154(9):1632-9. [DOI: 10.1016/j.pain.2013.04.044]
74. National Institute for Health and Care Excellence (NICE). Neuropathic pain - pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist settings, 2013. www.nice.org.uk/guidance/cg173 (accessed 30 November 2016).
75. Nüesch E, Trelle S, Reichenbach S, Rutjes AW, Tschannen B, Altman DG, et al. Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. BMJ 2010;341:c3515. [DOI: 10.1136/bmj.c3515]
76. O'Brien EM, Staud RM, Hassinger AD, McCulloch RC, Craggs JG, Atchison JW, et al. Patient-centered perspective on treatment outcomes in chronic pain. Pain Medicine 2010;11(1):6-15. [DOI: 10.1111/j.1526-4637.2009.00685]
77. Astellas PharmaEurope BV (Sponsor). A randomized, controlled, long-term safety study evaluating the effect of repeated applications of QUTENZATM plus standard of care versus standard of care alone in patients with painful diabetic peripheral neuropathy. www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=75 Date first received: 10 November 2011. [Astellas ID: E05-CL-3002; CTG: NCT01478607; EudraCT number: 2009-016458-42]
78. PaPaS author and referee guidance. papas.cochrane.org/papas-documents (accessed 30 November 2016).
79. Phillips TJ, Cherry CL, Cox S, Marshall SJ, Rice AS. Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials. PLoS One 2010;5(12):e14433.
80. Rappaport ZH, Devor M. Trigeminal neuralgia: the role of self-sustaining discharge in the trigeminal ganglion. Pain 1994;56:127-38. [DOI: 10.1016/0304-3959(94)90086-8]
81. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
82. Simpson DM, Brown S, Tobias JK, Vanhove GF, NGX-4010 C107 Study Group. NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: results of a 52-week open-label study. Clinical Journal of Pain 2014;30(2):134-42. [DOI: 10.1097/AJP.0b013e318287a32f]
83. Straube S, Derry S, Moore RA, McQuay HJ. Pregabalin in fibromyalgia: meta-analysis of efficacy and safety from company clinical trial reports. Rheumatology 2010;49(4):706-15. [DOI: 10.1093/rheumatology/kep432]
84. Straube S, Moore RA, Paine J, Derry S, Phillips CJ, Hallier E, et al. Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response. BMC Musculoskeletal Disorders 2011;12:125. [DOI: 10.1186/1471-2474-12-125]
85. TM for the treatment of peripheral neuropathic pain. www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=81 Date first received: 28 October 2010. [EudraCT number: 2009-016457-18]
86. Sultan A, Gaskell H, Derry S, Moore RA. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurology 2008;8:29. [DOI: 10.1186/1471-2377-8-9]
87. Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. Journal of Pain 2006;7(4):281-9. [DOI: 10.1016/j.jpain.2005.11.008]
88. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008;70(18):1630-5. [DOI: 10.1212/01.wnl.0000282763.29778.59]
89. van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain 2014;155(4):654-62. [DOI: 10.1016/j.pain.2013.11.013]
90. van Nooten FE, Charokopou M, Poole C, Treur M. A systematic literature review and network meta-analysis of capsaicin 8% patch versus oral neuropathic pain medications for the treatment of painful diabetic peripheral neuropathy. Value in Health 2015;18(7):A659. [DOI: 10.1016/j.jval.2015.09.2388]
91. von Hehn CA, Baron R, Woolf CJ. Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. Neuron 2012;73(4):638-52. [DOI: 10.1016/j.neuron.2012.02.008]
92. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380(9859):2163-96. [DOI: 10.1016/S0140-6736(12)61729-2]
93. Wiffen PJ, Derry S, Moore RA, Aldington D, Cole P, Rice ASC, et al. Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews. Cochrane Database of Systematic Reviews 2013, Issue 11. [DOI: 10.1002/14651858.CD010567.pub2]
94. Uçeyler N, Sommer C. High-dose capsaicin for the treatment of neuropathic pain: what we know and what we need to know. Pain and Therapy 2014;3(2):73-84. [DOI: 10.1007/s40122-014-0027-1]
95. Derry S, Lloyd R, Moore RA, McQuay HJ. Topical capsaicin for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD007393.pub2]
96. Derry S, Sven-Rice A, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews 2013, Issue 2. [DOI: 10.1002/14651858.CD007393.pub3]
97. Mason L, Moore RA, Derry S, Edwards JE, McQuay HJ. Systematic review of topical capsaicin for the treatment of chronic pain. BMJ (Clinical Research Ed) 2004;328(7446):991. [10.1136/bmj.38042.506748.EE]